Ltd provide high-quality, lab-tested Glutathione for skincare, supplements, and pharmaceutical applications
Inspired by Babu and Krishnan [1] review on PDTs effectiveness in oral cancer treatment, we explored LXD191, a novel therapeutic agent combining lipophilic diarylacetylene and hydroxamic acid (HA), for its dual-action mechanism of PDT and histone deacetylase (HDAC) inhibition [2,3,4]
doi:10.2340/actadv.v103.4536 Barel A, Calomme M, Timchenko A, De Paepe K, Demeester N, Rogiers V,
* Correspondence: Evgeny Ruchko, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
NICE guidance (NG28) recommends considering dose reductions of insulin or sulfonylureas when initiating a GLP-1 receptor agonist to mitigate this risk
Nakano Y, Asada K
